Search Results - Ukropec, Jon

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma by Fonseca, Rafael, Usmani, Saad Z., Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M., Nair, Sandhya, Potluri, Ravi, Voorhees, Peter M.

Get full text Get full text Get full text

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN by Voorhees, Peter M., Rodriguez, Cesar, Reeves, Brandi, Nathwani, Nitya, Costa, Luciano J., Lutska, Yana, Bobba, Padma, Hoehn, Daniela, Pei, Huiling, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Richardson, Paul G.

Get full text Get full text Get full text

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study by Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M., Narang, Mohit, Stevens, Don, Gunawardena, Sriya, Lutska, Yana, Qi, Keqin, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Rifkin, Robert M.

Get full text Get full text Get full text

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia by Cook, Gordon, Corso, Alessandro, Streetly, Matthew, Mendeleeva, Larisa P., Ptushkin, Vadim V., Chan, Edmond, Ukropec, Jon, Iraqi, Wafae, Al-Akabawi, Assem, Pei, Huiling, Gaudig, Maren, Petrucci, Maria Teresa, Alegre, Adrian, Mateos, Maria-Victoria

Get full text Get full text Get full text

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma by Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K.

Get full text Get full text Get full text

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma by Yan, Xiaoyu, Xu, Xu Steven, Weisel, Katja C., Mateos, Maria‐Victoria, Sonneveld, Pieter, Dimopoulos, Meletios A., Usmani, Saad Zafar, Bahlis, Nizar J., Puchalski, Thomas, Ukropec, Jon, Bellew, Kevin, Ming, Qi, Sun, Steven, Zhou, Honghui

Get full text Get full text Get full text

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma by Munshi, Nikhil C., Avet-Loiseau, Herve, Anderson, Kenneth C., Neri, Paola, Paiva, Bruno, Samur, Mehmet, Dimopoulos, Meletios, Kulakova, Margarita, Lam, Annette, Hashim, Mahmoud, He, Jianming, Heeg, Bart, Ukropec, Jon, Vermeulen, Jessica, Cote, Sarah, Bahlis, Nizar

Get full text Get full text Get full text

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses by Xu, Xu Steven, Moreau, Philippe, Usmani, Saad Z., Lonial, Sagar, Jakubowiak, Andrzej, Oriol, Albert, Krishnan, Amrita, Bladé, Joan, Luo, Man, Sun, Yu-Nien, Zhou, Honghui, Nnane, Ivo, Deraedt, William, Qi, Ming, Ukropec, Jon, Clemens, Pamela L.

Get full text Get full text Get full text

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma by Chari, Ajai, Martinez-Lopez, Joaquín, Mateos, María-Victoria, Bladé, Joan, Benboubker, Lotfi, Oriol, Albert, Arnulf, Bertrand, Rodriguez-Otero, Paula, Pineiro, Luis, Jakubowiak, Andrzej, de Boer, Carla, Wang, Jianping, Clemens, Pamela L., Ukropec, Jon, Schecter, Jordan, Lonial, Sagar, Moreau, Philippe

Get full text Get full text Get full text

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study by Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus

Get full text Get full text Get full text

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and... by Mateos, Maria-Victoria, Spencer, Andrew, Nooka, Ajay K., Pour, Ludek, Weisel, Katja, Cavo, Michele, Laubach, Jacob P., Cook, Gordon, Iida, Shinsuke, Benboubker, Lotfi, Usmani, Saad Z., Yoon, Sung-Soo, Bahlis, Nizar J., Chiu, Christopher, Ukropec, Jon, Schecter, Jordan M., Qin, Xiang, O’Rourke, Lisa, Dimopoulos, Meletios A.

Get full text Get full text Get full text

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR by Avet-Loiseau, Hervé, San-Miguel, Jesus, Casneuf, Tineke, Iida, Shinsuke, Lonial, Sagar, Usmani, Saad Z., Spencer, Andrew, Moreau, Philippe, Plesner, Torben, Weisel, Katja, Ukropec, Jon, Chiu, Christopher, Trivedi, Sonali, Amin, Himal, Krevvata, Maria, Ramaswami, Priya, Qin, Xiang, Qi, Mia, Sun, Steven, Qi, Ming, Kobos, Rachel, Bahlis, Nizar J.

Get full text Get full text Get full text

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE by San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, Bahlis, Nizar J.

Get full text Get full text Get full text

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA by Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Zweegman, Sonja

Get full text Get full text Get full text

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA by Cavo, Michele, San-Miguel, Jesus, Usmani, Saad Z., Weisel, Katja, Dimopoulos, Meletios A., Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J., Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W. C. J., Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, Munshi, Nikhil

Get full text Get full text Get full text

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial by Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.

Get full text Get full text Get full text

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) by Mateos, María-Victoria, Kumar, Shaji, Dimopoulos, Meletios A., González-Calle, Verónica, Kastritis, Efstathios, Hajek, Roman, De Larrea, Carlos Fernández, Morgan, Gareth J., Merlini, Giampaolo, Goldschmidt, Hartmut, Geraldes, Catarina, Gozzetti, Alessandro, Kyriakou, Charalampia, Garderet, Laurent, Hansson, Markus, Zamagni, Elena, Fantl, Dorotea, Leleu, Xavier, Kim, Byung-Su, Esteves, Graça, Ludwig, Heinz, Usmani, Saad, Min, Chang-Ki, Qi, Ming, Ukropec, Jon, Weiss, Brendan M., Rajkumar, S. Vincent, Durie, Brian G. M., San-Miguel, Jesús

Get full text Get full text Get full text

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX by Kaufman, Jonathan L., Dimopoulos, Meletios A., White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P., Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J., Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H., Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z., San-Miguel, Jesus

Get full text Get full text Get full text

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk by Weisel, Katja, Spencer, Andrew, Lentzsch, Suzanne, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay, Quach, Hang, Munder, Markus, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Casneuf, Tineke, DeAngelis, Nikki, Amin, Himal, Ukropec, Jon, Kobos, Rachel, Mateos, Maria-Victoria

Get full text Get full text Get full text